HC Wainwright Reiterates “$3.00” Price Target for Lipocine (LPCN)
Lipocine (NASDAQ:LPCN) has been given a $3.00 price target by stock analysts at HC Wainwright in a research note issued on Friday, MarketBeat.com reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 75.44% from the company’s previous close.
LPCN has been the topic of a number of other research reports. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $11.00 target price on shares of Lipocine in a research report on Thursday. Canaccord Genuity downgraded Lipocine from a “buy” rating to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.50.
Lipocine (NASDAQ:LPCN) traded down $0.16 during trading hours on Friday, hitting $1.71. The company had a trading volume of 1,578,100 shares, compared to its average volume of 622,569. The firm has a market capitalization of $36.25, a P/E ratio of -1.78 and a beta of 0.11. Lipocine has a twelve month low of $1.67 and a twelve month high of $5.33.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/13/hc-wainwright-reiterates-3-00-price-target-for-lipocine-lpcn.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.